Stockreport

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - New clinical data from second-line randomized ONSEMBLE trial provides further [Read more]